The Cancer Center at Illinois brings together cancer biologists, clinicians, engineers, and other specialists to accelerate advances in disease detection, prevention, therapy, and improve quality of life for patients.
Researchers at the University of Illinois Urbana-Champaign will develop a radically new platform to manufacture tumor models and expand their availability for medical research and personalized medicine, thanks to a $21 million grant from the Advanced Research Projects...
For typical illnesses, the body’s immune system is a robust, pathogen-killing machine. It provides a general defense against harmful germs while also adapting and producing antibodies that target specific bacteria or viruses. After fighting off an infection like the flu, the body produces...
Estrogen receptor-positive breast cancer is the most common form of breast cancer, affecting approximately 75 percent of breast cancer patients. In advanced and metastatic form, it is lethal, claiming the lives of nearly 350,000 individuals annually. Presently, no drug is able to eradicate these...
Scientists have identified a protein that plays a pivotal role in the action of several emerging cancer therapies. The researchers say the discovery will likely aid efforts to fine-tune the use of immunotherapies against several challenging cancers.
Through a new approach of cross-linking cell proteins directly to a protein of interest, researchers at the University of Illinois Urbana-Champaign’s School of Molecular & Cellular Biology have distinguished new patterns of cell interactions with a molecular chaperone.
The Beckman Institute has announced its 2023 class of six postdoctoral fellows. Fellows are selected in accordance with the core values of the institute: excellence, collaboration, integrity, transdisciplinarity, exploration, and diversity.
The SRSF1 gene acts as a guardian against DNA damage in the liver, School of MCB researchers found. When it is missing or inactivated, severe nonalcoholic fatty liver disease symptoms develop.
CHAMPAIGN, Ill. — Less than 20% of diagnosed breast cancers are designated “triple-negative,” meaning that the affected tissues lack three types of receptors often found in other breast cancer types, but TNBCs are often aggressive with ...
The Cancer Center at Illinois is proud to announce the selection of nine interdisciplinary cancer research projects, involving multiple MCB faculty members, designed by University of Illinois Urbana-Champaign faculty to be funded by Cancer Center at Illinois (CCIL) developmental grant awards.
Stephen G. Sligar has spent the last 40 years at the University of Illinois Urbana-Champaign applying his expertise in membrane proteins and his nanodisc technology to better understand biological pathways and address diseases including cancer.